EvoEndo’s system uses a single-use, flexible gastroscope and provides virtual reality entertainment for patients to allow the procedure to be performed without anesthesia or sedation.
Distribution will begin once the companies receive FDA 510(k) clearance, which requires companies to notify the federal agency of its intent to market a product at least 90 days in advance.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
